Second-line cannabis therapy in patients with epilepsy

Sekar, 2019, Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects, F1000Res, 8, 234, 10.12688/f1000research.16515.1 Elliott, 2020, Neurologists’ perspectives on medical cannabis for pediatric drug-resistant epilepsy in Canada: a qualitative interview study, Seizure, 78, 118, 10.1016/j.seizure.2020.04.002 Laux, 2019, Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results, Epilepsy Res, 154, 13, 10.1016/j.eplepsyres.2019.03.015 Commissioner O of the. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). FDA [Internet]. 2021 Oct 18 [cited 2022 Mar 5]; Available from: 〈https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd〉. Massot-Tarrús, 2016, Marijuana use in adults admitted to a Canadian epilepsy monitoring unit, Epilepsy Behav., 63, 73, 10.1016/j.yebeh.2016.08.002 Miller, 2020, Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: a randomized clinical trial, JAMA Neurol., 77, 613, 10.1001/jamaneurol.2020.0073 Thiele, 2018, GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet, 391, 1085, 10.1016/S0140-6736(18)30136-3